Evidence map›Paper›PMID 30978183›Full record

ArticlePLoS computational biology2019

Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size.

Daniel I S Rosenbloom, Peter Bacchetti, Mars Stone, Xutao Deng, Ronald J Bosch, Douglas D Richman, Janet D Siliciano, John W Mellors, Steven G Deeks, Roger G Ptak and 9 more

Open access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. TILDA: Tat/Rev Induced Limiting Dilution Assay.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Measuring the Success of HIV-1 Cure Strategies.Frontiers in cellular and infection microbiology · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 1 country.

Daniel I S RosenbloomDepartment of Systems Biology, Columbia University College of Physicians and Surgeons, New York, New York, United States of America.ORCID 0000-0003-1413-3907
Peter BacchettiDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America.
Mars StoneBlood Systems Research Institute, San Francisco, California, United States of America.ORCID 0000-0001-5619-2767
Xutao DengBlood Systems Research Institute, San Francisco, California, United States of America.
Ronald J BoschCenter for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Douglas D RichmanUniversity of California San Diego, La Jolla, California, United States of America.
Janet D SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
John W MellorsDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.ORCID 0000-0002-3737-9742
Steven G DeeksDivision of HIV, Infectious Diseases and Global Medicine, University of California San Francisco, San Francisco, California, United States of America.
Roger G PtakSouthern Research, Frederick, Maryland, United States of America.
Rebecca HohDivision of HIV, Infectious Diseases and Global Medicine, University of California San Francisco, San Francisco, California, United States of America.
Sheila M KeatingBlood Systems Research Institute, San Francisco, California, United States of America.ORCID 0000-0002-8324-3694
Melanie DimapasocBlood Systems Research Institute, San Francisco, California, United States of America.
Marta MassanellaUniversity of California San Diego, La Jolla, California, United States of America.
Jun LaiDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Michele D SobolewskiDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
Deanna A KulpaSouthern Research, Frederick, Maryland, United States of America.
Michael P BuschBlood Systems Research Institute, San Francisco, California, United States of America.ORCID 0000-0002-1446-125X
Reservoir Assay Validation and Evaluation Network (RAVEN) Study Group
University of California, San Francisco · USBlood Systems Research Institute · USJohns Hopkins University · USSouthern Research Institute · USUniversity of California San Diego · USUniversity of Pittsburgh · USCancer Research And Biostatistics · USColumbia University · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2M
NCATS NIH HHS UL1 TR001442NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI050409NIAID NIH HHS UM1 AI126619NIAID NIH HHS UM1 AI126620
6 · The paper itself

Abstract

Quantitative viral outgrowth assays (QVOA) use limiting dilutions of CD4+ T cells to measure the size of the latent HIV-1 reservoir, a major obstacle to curing HIV-1. Efforts to reduce the reservoir require assays that can reliably quantify its size in blood and tissues. Although QVOA is regarded as a "gold standard" for reservoir measurement, little is known about its accuracy and precision or about how cell storage conditions or laboratory-specific practices affect results. Owing to this lack of knowledge, confidence intervals around reservoir size estimates-as well as judgments of the ability of therapeutic interventions to alter the size of the replication-competent but transcriptionally inactive latent reservoir-rely on theoretical statistical assumptions about dilution assays. To address this gap, we have carried out a Bayesian statistical analysis of QVOA reliability on 75 split samples of peripheral blood mononuclear cells (PBMC) from 5 antiretroviral therapy (ART)-suppressed participants, measured using four different QVOAs at separate labs, estimating assay precision and the effect of frozen cell storage on estimated reservoir size. We found that typical assay results are expected to differ from the true value by a factor of 1.6 to 1.9 up or down. Systematic assay differences comprised a 24-fold range between the assays with highest and lowest scales, likely reflecting differences in viral outgrowth readout and input cell stimulation protocols. We also found that controlled-rate freezing and storage of samples did not cause substantial differences in QVOA compared to use of fresh cells (95% probability of < 2-fold change), supporting continued use of frozen storage to allow transport and batched analysis of samples. Finally, we simulated an early-phase clinical trial to demonstrate that batched analysis of pre- and post-therapy samples may increase power to detect a three-fold reservoir reduction by 15 to 24 percentage points.

Indexed as

HIV-1Virus LatencyAnti-HIV AgentsBayes TheoremCD4-Positive T-LymphocytesComputational BiologyComputer SimulationHIV InfectionsHumansLeukocytes, MononuclearLikelihood FunctionsMarkov ChainsMonte Carlo MethodReproducibility of ResultsViral LoadVirus ReplicationAnti-HIV Agents

Identifiers

PMID30978183
PMCPMC6481870
OpenAlexW2949723271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.